The two sides conducted in-depth discussions on topics such as clinical CRO, subject recruitment, and post-marketing digital marketing of drugs

On April 13, Shen Peng, founder, chairman and CEO of Shuidi Company (WDH.US), led the core head of Shuidi's pharmaceutical innovation business and others to visit the Nanjing Shunxin factory area of the Hong Kong-listed company China Biopharmaceutical (01177). Xie Chengrun, chairman of Chia Tai Tianqing Pharmaceutical Group, led the executive team with a cordial reception. The two sides conducted in-depth discussions on topics such as clinical CRO, subject recruitment, and post-marketing digital marketing of drugs, and reached a number of agreements to achieve win-win development and continue to deepen strategic cooperation.

Shuidi and his entourage visited Chia Tai Tianqing Pharmaceutical Group and had in-depth exchanges

Xie Chengrun, chairman of Chia Tai Tianqing Pharmaceutical Group, first welcomed the arrival of Shuidi and his entourage. In his speech, he said, “As China's leading innovative pharmaceutical group enterprise integrating scientific research, production and sales, Chia Tai Tianqing Pharmaceutical Group is committed to providing patients with better health solutions and high-quality and affordable pharmaceutical resources, creating a collaborative loop of 'medicine+drug+insurance'. Meanwhile, the rich patient service experience and ability accumulated by Shuidi Company can complement Chia Tai Tianqing well. We look forward to the two sides continuing to deepen cooperation and achieve win-win development.” Subsequently, he also gave many valuable feasibility suggestions for Shuidi to start a pharmaceutical business.

Xie Chengrun, Chairman of Chia Tai Tianqing Pharmaceutical Group

Shen Peng, founder, chairman and CEO of Shuidi, thanked Chia Tai Tianqing Pharmaceutical Group for recognizing Shuidi and was pleased with the results achieved in previous cooperation between the two parties. Shen Peng pointed out, “Chia Da Tianqing is Shuidi's partner with the largest business volume and the closest collaboration in the pharmaceutical field. The two sides have jointly pioneered and innovated in previous cooperation and achieved excellent results in many projects. We look forward to continuing to move forward together to achieve more in-depth cooperation results in more fields to benefit more patients.”

Shen Peng, founder, chairman and CEO of Shuidi

In discussions on strategic cooperation surrounding clinical trials, Dr. Zhao Wei, vice president of Chia Tai Tianqing Pharmaceutical Group and general manager of Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd., said that in recent years, Chia Tai Tianqing has adhered to the concept of innovation-driven development and continued to increase investment in research and development. More than 70 innovative drugs and biosimilar drugs are being promoted clinically. “The Shuidi Wifan Pharmaceutical platform is Chia Tai Tianqing's largest partner in the field of clinical trial subject recruitment. The cooperative business volume continues to grow. The business volume of Chia Tai Tianqing's business accounts for nearly 50% of Chia Tai Tianqing's more than 20 partners in this field, effectively promoting the development progress of the Chia Tai Tianqing clinical trial.” Dr. Zhao Wei said.

Dr. Zhao Wei, Vice President of Chia Tai Tianqing Pharmaceutical Group and General Manager of Shanghai Zhengda Tianqing Pharmaceutical Technology Development Co., Ltd.

Zhu Zetao, partner of Shuidi Company and general manager of Shuidi Funding and Pharmaceutical Business Group, said that with the mission of “protecting hundreds of millions of families,” Shuidi Company revolves around millions of patients with major diseases served by Water Drop, combined with the medical technology capabilities accumulated over the years, pioneered innovative services such as clinical trial CRO and digital recruitment of test subjects to provide more choices for patients with major diseases and improve the efficiency and quality of innovative drug development. Compared to traditional CRO companies that provide one-stop clinical trial services, Yifan Pharmaceutical's CRO business involves the applicant from the applicant's R&D project establishment stage, providing the applicant with a full life cycle of services such as data insight, clinical trial plan strategy formulation, quick start-up, quick enrolment, rapid delivery, patient management, early business planning, doctor training, and post-marketing sales channel maintenance.

Zhu Zetao, Partner of Shuidi Company and General Manager of Shuidi Funding and Pharmaceutical Business Group

On the same day, Shuidi Company and Chia Tai Tianqing Pharmaceutical Group also discussed strategic cooperation in the field of digital marketing. The two sides highly agree to strengthen strategic cooperation in the field of digital marketing. On the basis of previous cooperation, in-depth discussions have been conducted around patient-centered and continuously improving the value level of patients, and have reached cooperation intentions on multiple dimensions.

Participants from both sides had on-site exchanges

Yu Kangxin, executive vice president of Chia Tai Tianqing Pharmaceutical Group, said, “Chia Tai Tianqing Pharmaceutical Group adheres to the concept of innovation-driven development and continues to explore the digital field. “Shuidi Company and Chia Tai Tianqing have not only been able to successfully complement each other's strengths, but have also established a good relationship of mutual trust based on previous cooperation.”

Yu Kangxin, Executive Vice President of Chia Tai Tianqing Pharmaceutical Group

Hu Yao, co-founder of Shuidi Company and head of strategy and investment in the pharmaceutical field, said that Shuidi adheres to the “patient-centered” service purpose, provides accurate services such as finding money and medicine to 3 million patients with major illnesses, has accumulated rich operating experience, accumulated a knowledge map of diseases, operation systems and leading algorithm capabilities, and built a unique doctor-patient private domain operation system with “high retention rate and high satisfaction”, eventually forming Shuidi's unique one-stop private area management platform.

Hu Yao, co-founder of Shuidi and head of strategy and investment in the pharmaceutical sector

According to reports, as the core enterprise of China Biopharmaceutical (01177), a Hong Kong-listed company, Chia Tai Tianqing Pharmaceutical Group is a leading innovative pharmaceutical group enterprise in China that has achieved remarkable results in clinical trials and drug research and development. Meanwhile, Shuidi has provided strong support for Chia Tai Tianqing in the field of clinical trials with its huge population of seriously ill patients, medical technology, and innovative services.

Group photo of participants from Shuidi Company and Chia Tai Tianqing Pharmaceutical Group

Looking ahead, Shuidi and Chia Tai Tianqing Pharmaceutical Group will continue to deepen strategic cooperation. This will help achieve mutual benefit and win-win situation in the field of clinical trials, work together to promote innovation and development in the pharmaceutical industry, and bring more innovative drugs and efficient treatment solutions to patients.